Stock Price Prediction

OPT stock has a bullish outlook, with analysts highlighting its innovative therapy sozinibercept (OPT-302) for wet AMD. JonesTrading maintains a Buy rating with a $13 price target, citing strong Phase 3 trial potential and market differentiation. The current price of $5.56 suggests significant upside if trial results meet expectations.

OPT stock closed at $5.56 on January 31, 2025, up 1.28% during regular trading. Despite a positive outlook from analysts like JonesTrading, who maintain a $13.00 price target, the current price reflects skepticism about upcoming trial results for sozinibercept in wet AMD. Bearish sentiment may stem from the stock's low trading volume and lack of immediate catalysts.